Literature DB >> 15673846

Increased hepatobiliary clearance of unconjugated thyroxine determines DMP 904-induced alterations in thyroid hormone homeostasis in rats.

Harvey Wong1, Lois D Lehman-McKeeman, Mary F Grubb, Scott J Grossman, Vasanthi M Bhaskaran, Eric G Solon, Helen S L Shen, Ronald J Gerson, Bruce D Car, Bitao Zhao, Brian Gemzik.   

Abstract

4-(3-pentylamino)-2,7-dimethyl-8-(2-methyl-4-methoxyphenyl)-pyrazolo-[1,5-a]-pyrimidine (DMP 904) is a potent and selective antagonist of corticotropin releasing factor receptor-1 (CRF1 receptor) with an efficacious anxiolytic profile in preclinical animal models. In subchronic toxicity studies in Sprague-Dawley rats, DMP 904 produced thyroid follicular cell hypertrophy and hyperplasia, and a low incidence of follicular cell adenoma. The current investigations were designed to determine the mode of action by which DMP 904 disrupts thyroid homeostasis in male rats. Five-day treatment with DMP 904 (300 mg/kg/day) dramatically lowered serum thyroxine (T4) to levels below detectable limits (< 1 microg/dl) by 72 h, with concurrent decreases in triiodothyronine (T3, about a 70% decrease) and increases in thyroid stimulating hormone (TSH; about a three-fold increase). DMP 904 increased [125I]T4 total body clearance (Cl tb) (38.21 +/- 10.45 ml/h) compared to control (5.61 +/- 0.59 ml/h) and phenobarbital-treated rats (7.92 +/- 1.62 ml/h). This increase in Cl(tb) was associated with a significant increase in biliary clearance (Cl bile) of unconjugated [125I]T4 (nearly 80-times control rates) and increased liver:blood ratios of T4, suggestive of enhanced hepatic uptake of T4. A single dose of DMP 904 (200 mg/kg) increased mRNA levels of hepatic cytochrome P450s (CYP 3A1 and CYP 2B1) and UDP-glucuronosyltransferases (UGT 1A1 and UGT 1A2). DMP 904 also induced mRNAs of the canalicular transporter, multi-drug resistance protein-2 (Mrp2) and sinusoidal transporters, organic anion transporting proteins (Oatp1 and Oatp2) within 24 h. Western blot analysis confirmed DMP 904 related increases in Oatp2 protein expression. Collectively, these data suggest that DMP 904 is an agonist of the constitutive androstane receptor (CAR) and pregnane X receptor (PXR) and that the decreased serum levels of T4 and T3 resulted from increased hepatobiliary clearance. However, DMP 904 is distinguished from other compounds associated with similar effects on thyroid hormone homeostasis because its effects were primarily related to increased biliary excretion of unconjugated T4.

Entities:  

Mesh:

Substances:

Year:  2005        PMID: 15673846     DOI: 10.1093/toxsci/kfi094

Source DB:  PubMed          Journal:  Toxicol Sci        ISSN: 1096-0929            Impact factor:   4.849


  9 in total

1.  Camptothecin attenuates cytochrome P450 3A4 induction by blocking the activation of human pregnane X receptor.

Authors:  Yakun Chen; Yong Tang; Gregory T Robbins; Daotai Nie
Journal:  J Pharmacol Exp Ther       Date:  2010-05-26       Impact factor: 4.030

2.  Polychlorinated biphenyl congeners that increase the glucuronidation and biliary excretion of thyroxine are distinct from the congeners that enhance the serum disappearance of thyroxine.

Authors:  L A Martin; D T Wilson; K R Reuhl; M A Gallo; C D Klaassen
Journal:  Drug Metab Dispos       Date:  2011-12-20       Impact factor: 3.922

3.  Regulation of constitutive androstane receptor and its target genes by fasting, cAMP, hepatocyte nuclear factor alpha, and the coactivator peroxisome proliferator-activated receptor gamma coactivator-1alpha.

Authors:  Xunshan Ding; Kristin Lichti; Insook Kim; Frank J Gonzalez; Jeff L Staudinger
Journal:  J Biol Chem       Date:  2006-07-05       Impact factor: 5.157

4.  Developmental triclosan exposure decreases maternal, fetal, and early neonatal thyroxine: a dynamic and kinetic evaluation of a putative mode-of-action.

Authors:  Katie B Paul; Joan M Hedge; Ruby Bansal; R Thomas Zoeller; Robert Peter; Michael J DeVito; Kevin M Crofton
Journal:  Toxicology       Date:  2012-06-01       Impact factor: 4.221

5.  Disease-Associated Changes in Drug Transporters May Impact the Pharmacokinetics and/or Toxicity of Drugs: A White Paper From the International Transporter Consortium.

Authors:  Raymond Evers; Micheline Piquette-Miller; Joseph W Polli; Frans G M Russel; Jason A Sprowl; Kimio Tohyama; Joseph A Ware; Saskia N de Wildt; Wen Xie; Kim L R Brouwer
Journal:  Clin Pharmacol Ther       Date:  2018-07-12       Impact factor: 6.875

6.  Short-term exposure to triclosan decreases thyroxine in vivo via upregulation of hepatic catabolism in Young Long-Evans rats.

Authors:  Katie B Paul; Joan M Hedge; Michael J DeVito; Kevin M Crofton
Journal:  Toxicol Sci       Date:  2009-11-12       Impact factor: 4.849

7.  Evaluating Chemicals for Thyroid Disruption: Opportunities and Challenges with in Vitro Testing and Adverse Outcome Pathway Approaches.

Authors:  Pamela D Noyes; Katie Paul Friedman; Patience Browne; Jonathan T Haselman; Mary E Gilbert; Michael W Hornung; Stan Barone; Kevin M Crofton; Susan C Laws; Tammy E Stoker; Steven O Simmons; Joseph E Tietge; Sigmund J Degitz
Journal:  Environ Health Perspect       Date:  2019-09-05       Impact factor: 9.031

Review 8.  Metabolism-Disrupting Chemicals and the Constitutive Androstane Receptor CAR.

Authors:  Jenni Küblbeck; Jonna Niskanen; Paavo Honkakoski
Journal:  Cells       Date:  2020-10-15       Impact factor: 6.600

Review 9.  Biology of PXR: role in drug-hormone interactions.

Authors:  Jing Wang; Shu Dai; Yan Guo; Wen Xie; Yonggong Zhai
Journal:  EXCLI J       Date:  2014-07-07       Impact factor: 4.068

  9 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.